Versant-backed Ventus scores $100M round to turbocharge its dual-platform play at 'drugging the undruggable'
If one thing is true in biopharma venture capital, it’s that investors love a platform play. Now, a biotech with personnel split across the US and Canada is rolling in a rush of investor cash to advance its pursuit of “drugging the undruggable” with a dual platform it believes could help build a better small molecule.
Waltham, MA- and Montreal-based Ventus has snared a $100 million Series B to advance its five compounds, including an NLRP3 inflammasome small molecule inhibitor the biotech thinks could offer a much greater degree of chemical diversity than its rivals, the company said Thursday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 106,500+ biopharma pros reading Endpoints daily — and it's free.